{"id":536328,"date":"2010-04-21T00:01:48","date_gmt":"2010-04-21T04:01:48","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=74729"},"modified":"2010-04-21T00:01:48","modified_gmt":"2010-04-21T04:01:48","slug":"oracle-acquires-phase-forward-diax-collects-up-to-12m-from-paul-capital-agios-gets-130m-from-celgene-more-boston-area-deals-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/536328","title":{"rendered":"Oracle Acquires Phase Forward, Diax Collects Up to $12M from Paul Capital, Agios Gets $130M from Celgene, & More Boston-Area Deals News"},"content":{"rendered":"\n
Roundup<\/a>, deals<\/a>, funding<\/a><\/div>\n

\t\tErin Kutz wrote:<\/strong><\/p>\n

Acquisitions, partnership agreements, and early round financing for some stealthy operations made it a busy deals news week for us.<\/p>\n

—Third Rock Ventures, a Boston firm focused on investments in life sciences companies, plans to raise $400 million for its second fund<\/a>, according to an SEC filing. The firm closed its first fund, with $378 million, in 2007.<\/p>\n

—Waltham, MA-based scientific instrument maker PerkinElmer revealed it agreed to acquire Spokane, WA-based Signature Genomic Laboratories<\/a> for about $90 million in cash.<\/p>\n

—Foundation Medicine, a company that’s focused on fighting cancer by testing for genetic traits in a tumor and matching them with treatments, reported that it pulled in part of a $25 million Series A funding round<\/a>. The startup is incubated out of Boston’s Third Rock Ventures, which also led the financing. In February, Ryan was the first to report that former CombinatoRx (NASDAQ: CRXX<\/a>) CEO Alexis Borisy was leading Foundation.<\/p>\n

—Catabasis Pharmaceuticals, a Cambridge-based startup run by Sirtris Pharmaceuticals veterans, revealed in a regulatory filing that it pulled in $7.7 million of a planned $39.7 million financing<\/a>. The stealthy operation is developing treatments for inflammatory and metabolic diseases by leveraging the protective effects of omega-3 fatty acids.<\/p>\n

—Cambridge’s Agios Pharmaceuticals nabbed $130 million from Summit, NJ-based Celgene<\/a> (NASDAQ: CELG<\/a>), in exchange for an exclusive option to license and develop Agios’ experimental cancer drugs, for a certain span of time. The deal essentially makes the Cambridge company Celgene’s cancer metabolism drug unit without outright acquiring it.<\/p>\n

—The Daily Grommet, a Lexington, MA-based e-commerce company that promotes consumer products with online videos, has raised $3.4 million<\/a> in Series A funding. The financing included …Next Page »<\/a><\/span><\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, deals, funding Erin Kutz wrote: Acquisitions, partnership agreements, and early round financing for some stealthy operations made it a busy deals news week for us. —Third Rock Ventures, a Boston firm focused on investments in life sciences companies, plans to raise $400 million for its second fund, according to an SEC filing. The firm […]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7,10],"tags":[],"class_list":["post-536328","post","type-post","status-publish","format-standard","hentry","category-internet","category-news","category-software"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/536328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=536328"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/536328\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=536328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=536328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=536328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}